Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failureopen access
- Authors
- Park, Dong-Jin; Choi, Sung-Eun; Kang, Ji-Hyoun; Shin, Kichul; Sung, Yoon-Kyoung; Lee, Shin-Seok
- Issue Date
- Apr-2022
- Publisher
- SAGE PUBLICATIONS LTD
- Keywords
- JAK inhibitor; rheumatoid arthritis; switching; treatment continuation; TNF inhibitor
- Citation
- THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, v.14, pp.1 - 15
- Indexed
- SCIE
SCOPUS
- Journal Title
- THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
- Volume
- 14
- Start Page
- 1
- End Page
- 15
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/138819
- DOI
- 10.1177/1759720X221091450
- ISSN
- 1759-720X
- Abstract
- Objectives: Despite improved care for rheumatoid arthritis (RAI patients, many still experience treatment failure with biologic disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic DMARDs [tsDMARDs; typically Janus kinase inhibitors (JAKi)], and eventually switch to other agents. We compared the efficacy of a second tumor necrosis factor inhibitor (TNFi) and non-TNF-targeted treatment as the second-line treatment in patients showing an insufficient response to the first TNFi.
Methods: Patients were included if they had received at least one prescription for a TNFi, and at least one follow-up prescription for a second TNFi or non-TNF-targeted treatment after discontinuation of the first drug. In total, 209 patients were analyzed, including 69 with a second TNFi and 140 with a non-TNF-targeted treatment (106 non-TNFi biologics and 34 JAKi). Cox regression was used to estimate the hazard ratio (HR) for discontinuation.
Results: The mean follow-up period after switching was 28.0 (range: 0-80) months and 24.4% of the 209 patients switched or discontinued the second drug. In multivariate Cox proportional hazard analysis, the non-TNF-targeted treatment group had a lower likelihood of discontinuing their treatment than the second TNFi group [HR=0.326, 95% confidence interval (CI): 0.170-0.626, p=0.001]. When analyzed separately, the risk of discontinuation was significantly lower in both the non-TNFi biologic (HR=0.318, 95% CI: 0.160-0.633, p=0.001) and JAKi (HR= 0.356, 95% CI: 0.129-0.980, p=0.046) groups than in the second TNFi group.
Conclusion: Our study supported switching to a non-TNF-targeted treatment instead of TNF cycling in patients with RA showing an inadequate response to initial TNFi.
Results: The mean follow-up period after switching was 28.0 (range: 0–80) months and 24.4% of the 209 patients switched or discontinued the second drug. In multivariate Cox proportional hazard analysis, the non-TNF-targeted treatment group had a lower likelihood of discontinuing their treatment than the second TNFi group [HR = 0.326, 95% confidence interval (CI): 0.170–0.626, p = 0.001]. When analyzed separately, the risk of discontinuation was significantly lower in both the non-TNFi biologic (HR = 0.318, 95% CI: 0.160–0.633, p = 0.001) and JAKi (HR = 0.356, 95% CI: 0.129–0.980, p = 0.046) groups than in the second TNFi group.
Conclusion: Our study supported switching to a non-TNF-targeted treatment instead of TNF cycling in patients with RA showing an inadequate response to initial TNFi.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/138819)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.